Effectiveness of Pre-exposure Prophylaxis with Tixagevimab–Cilgavimab for COVID-19 Hospitalization among Chronic Kidney Disease Patients in Thailand: A Retrospective Cohort Study, August 2022 to May 2023

Read full text Summarise with VIRAT
Authors: Natthaprang Nittayasoot, Panithee Thammawijaya, Suphanat Wongsanuphat, Rapeepong Suphanchaimat, Supansa Suriya, Chakkarat Pittayawonganon
Cited by: 0
References: 23

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objectives: To evaluate the effectiveness of tixagevimab–cilgavimab in preventing COVID-19-related hospitalizations among chronic kidney disease (CKD) patients in Thailand from 1 Aug 2022 to 30 May 2023. Methods: We conducted a retrospective cohort study using secondary data from Thailand’s national health databases among CKD patients aged ≥12 years under the Universal Coverage Scheme who were followed from 1 Aug 2022 to 30 May 2023. The primary outcome was time until COVID-19 hospitalization, analyzed using Cox regression, and adjusted for age, gender, vaccination status, and comorbidities. Receiving tixagevimab–cilgavimab at a dose of either 300 mg or 600 mg was the main explanatory variable. A stratified analysis was also conducted by history of dialysis. Results: Among 1,018,175 CKD patients, tixagevimab–cilgavimab recipients had a higher hazard of hospitalization compared to non-recipients (adjusted hazard ratio 1.70; 95% confidence interval (CI) 1.40–2.06). Among dialysis patients, administration of tixagevimab–cilgavimab was associated with a non-significant reduction in the risk of hospitalization (effectiveness 18.15%; 95% CI: -12.82–40.62) while COVID-19 vaccination was strongly protective in both groups, with five doses showing an effectiveness of 79.18% (95% CI 61.28–88.80). Tixagevimab–cilgavimab did not significantly reduce the hazard of hospitalization overall but showed a non-significant trend toward a benefit among dialysis patients. Public Health Recommendations: Tailored prophylaxis strategies are needed for immunocompromised populations during evolving waves of COVID-19 variants. Further studies should assess effectiveness by variant period and underlying risk profile to better identify subgroups most likely benefit from the interventions.

Fields of Study & Subjects

SARS-CoV-2 and COVID-19 Research COVID-19 Clinical Research Studies COVID-19 epidemiological studies

Publication details

Journal / source
Outbreak Surveillance Investigation & Response (OSIR) Journal
Volume
19
Issue
1
Pages
279468–279468
Publication date
20 March 2026
Language
EN